On the clinician side, clinicians need to be informed and become competent in this area
603 In an 18-month proof-of-concept open-label randomized study, no statistically significant treatment group differences in the prevalence of confirmed clinical neuropathy (CCN), IENFD, and nerve conductions were observed
attl [13]
Explore our diverse range of pharmaceutical manufacturing categories, designed to deliver high-quality, reliable, and innovative healthcare solutions across multiple dosage forms
While all of these potential benefits are exciting, experts said they need much more study, and even then, whether they might ever be utilized as a treatment for schizophrenia, for example, would depend on a number of factors: how much and how consistently they work, as well as how they compare to treatments that are already available
September 2019